tqb2825
Follicular Lymphoma
Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.Phase 3Active
CCC
52/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 45/ 100
- Competitive Position
- 65/ 100
Competitive context
209 Active assets in the Follicular Lymphoma cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
CYCLOSPORIN A Fred Hutchinson Cancer Center | Phase 2/3 | BBB |
Romidepsin City of Hope Medical Center | Phase 2 | BBB |
VINCRISTINE SULFATE National Cancer Institute (NCI) | Phase 3 | BBB |
Irinotecan University of Michigan Rogel Cancer Center | Phase 2 | BBB |
Recombinant Human Hyaluronidase National Cancer Institute (NCI) | Phase 3 | BBB |
View all 50 →
Same molecule, other indications
tqb2825 is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →